A peptide-targeting immunology approach showed movement toward disease modification in Alzheimer’s disease by introducing a candidate framed as an mtCI mild modulator. The report positions the therapy within a broader strategy aimed at restoring cellular resilience rather than simply suppressing downstream pathology. Separately, a study mapped how a chemical “molecular brake” can modulate cancer immunity, reporting that a common bile-acid drug unlocked an immune control mechanism triggered by radiation-driven tumor responses. The work ties small-molecule biology to combinatorial oncology strategies with radiotherapy. Both updates underscore the continuing shift toward mechanism-first combinations—where new agents are paired with established modalities to improve outcomes through immune or cellular-state control.